Core E: Laboratory and biobehavioral marker core
核心 E:实验室和生物行为标记核心
基本信息
- 批准号:10090667
- 负责人:
- 金额:$ 23.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-06-03 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAcquired Immunodeficiency SyndromeAutoimmunityBehavior TherapyBehavioralBig DataBiochemical MarkersBioinformaticsBiologicalBiological AssayBiological MarkersBiometryBody FluidsCardiovascular systemCellsCerebrovascular CirculationClinicalClinical DataClinical assessmentsCognitiveCollaborationsDataData SetDatabasesDevelopmentDiffusionDiseaseDopamineEmotionsEnrollmentFunctional Magnetic Resonance ImagingGenomic DNAGenotypeGurHIVHIV InfectionsHealthImageImmune responseImmunityImmunosuppressionImmunotherapyIndividualInfectionInflammationInterventionIntervention StudiesKidneyLaboratoriesLeadershipLinkMagnetic Resonance ImagingMeasurementMeasuresMedicalMental HealthMental disordersMetabolicMissionModelingMolecular VirologyMonitorMorbidity - disease rateNeurocognitiveNeuropsychologyOutcomeOutputParticipantPathway interactionsPediatric HospitalsPennsylvaniaPersonsPharmacologyPhenotypePhiladelphiaPhysiologicalPilot ProjectsPlasmaPopulationPositioning AttributePositron-Emission TomographyPsychiatryPublic Health InformaticsQuality ControlRecordsResearchResearch PersonnelResourcesRestRewardsRoleSamplingSchoolsSensory ReceptorsSerotoninSerumSpecimenSpin LabelsStandardizationStressStructureTechniquesTestingTherapeuticUniversitiesViralWorkbehavior testbehavioral pharmacologybiobankbiobehaviorbiomedical informaticsblood oxygen level dependentbonebrain behaviorcohortcomorbiditycomputerizedcomputerized data processingdata managementdesignimmune activationlaboratory experimentmedical schoolsmetabolomicsmicrobiomenervous system disorderneuroAIDSneurobehavioralneuroimagingnovelprogramsquality assuranceranpirnaserepositorysingle photon emission computed tomographytranscriptome sequencing
项目摘要
CORE E: ABSTRACT/SUMMARY
Consistent with the Center's theme, the mission of Core E is to facilitate a broad range of biological and
behavioral intervention studies that are designed to optimize psychiatric, behavioral, and medical outcomes
among HIV infected individuals. The Core will perform assays for all Pilot Projects, as well as design and
implement novel assays. This Core will perform laboratory and imaging assessments that define the mental
illnesses and co-morbidities related to HIV/AIDS and unique modeling and measurements related to various
behavioral and pharmacologic interventions. The Core will benefit from the major strengths of the Perelman
School of Medicine (PSOM), CHOP, Centers, Departments, and Schools at UPenn. We will identify specific
and potentially unique biomarkers which are related to mental illness and to comorbidities of HIV/AIDS. These
data will be collected for all subjects to be studied in pilots and other Cores. The Core will perform assays of
body fluids and cells including markers of immunity, inflammation, stress, and health. The Core will also carry
out neuroimaging and neurocognitive measures. The Core will assessments related to therapeutics for HIV,
mental health, and co-morbidities. The Core is directed by two senior investigators, Drs. Douglas and Gur. The
Core will support the Center's scientific agenda and developmental program. This Core resource will closely
interact with existing resources at UPenn, which are central to the mission of the PMHARC. The Core Director,
Douglas, and Co-Director, Gur, are in leadership roles at UPenn. The Core will be uniquely positioned to carry
out and monitor the quality control and quality assurance of standardized selected imaging, biochemical
markers, neuropsychological behavioral testing, and laboratory testing. The Core will work closely with all the
other PMHARC Cores, and most closely with the Clinical Assessment Core, in an effort to gather integrated
'state-of-the-art' biomedical and behavioral data on a cohort of HIV+ persons with a variety of mental illnesses
in an effort to better understand disease trajectories, morbidities and clinical outcomes.
核心E:摘要/摘要
与中心的主题一致,核心E的使命是促进广泛的生物学和
旨在优化精神病,行为和医学结果的行为干预研究
在艾滋病毒感染的人中。核心将对所有试点项目以及设计和设计进行测定
实施新颖的测定。该核心将进行实验室和成像评估,以定义精神
与艾滋病毒/艾滋病有关的疾病和合并症以及与各种相关的独特建模和测量
行为和药理干预措施。核心将从佩雷尔曼的主要优势中受益
upenn的医学院(PSOM),CHOP,中心,部门和学校。我们将确定具体
以及与精神疾病和艾滋病毒/艾滋病合并症有关的潜在独特的生物标志物。这些
将收集数据,以便在飞行员和其他核心中研究所有受试者。核心将执行测定
体液和细胞,包括免疫,炎症,压力和健康的标志。核心也将携带
消除神经影像学和神经认知措施。与艾滋病毒治疗剂有关的核心意愿评估,
心理健康和合并症。核心由两名高级调查员Drs指导。道格拉斯和古尔。这
核心将支持该中心的科学议程和发展计划。这个核心资源将密切
与UPENN的现有资源互动,这是PMHARC任务的核心。核心主任,
道格拉斯(Douglas)和联合导演古尔(Gur)担任乌普恩(Upenn)的领导职务。核心将是独特的位置
淘汰并监视标准化成像,生化的质量控制和质量保证
标记,神经心理学行为测试和实验室测试。核心将与所有
其他PMHARC核心,最与临床评估核心最紧密的核心,以收集综合
艾滋病毒+患者的“最先进”生物医学和行为数据有多种精神疾病
为了更好地了解疾病轨迹,病态和临床结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven Daniel Douglas其他文献
Steven Daniel Douglas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven Daniel Douglas', 18)}}的其他基金
NeuroAIDS Therapeutics-Targeting Immune Polarization of Macrophages in CNS
神经艾滋病治疗——针对中枢神经系统巨噬细胞的免疫极化
- 批准号:
8929300 - 财政年份:2014
- 资助金额:
$ 23.82万 - 项目类别:
NeuroAIDS Therapeutics-Targeting Immune Polarization of Macrophages in CNS
神经艾滋病治疗——针对中枢神经系统巨噬细胞的免疫极化
- 批准号:
9288214 - 财政年份:2014
- 资助金额:
$ 23.82万 - 项目类别:
NeuroAIDS Therapeutics-Targeting Immune Polarization of Macrophages in CNS
神经艾滋病治疗——针对中枢神经系统巨噬细胞的免疫极化
- 批准号:
8790645 - 财政年份:2014
- 资助金额:
$ 23.82万 - 项目类别:
NEUROKININ-1 RECEPTOR EXPRESSION IN THE BRAINS OF SIV-INFECTED RHESUS MACAQUES
感染 SIV 的恒河猴大脑中 NEUROKININ-1 受体的表达
- 批准号:
8358142 - 财政年份:2011
- 资助金额:
$ 23.82万 - 项目类别:
NEUROKININ-1 RECEPTOR EXPRESSION IN THE BRAINS OF SIV-INFECTED RHESUS MACAQUES
感染 SIV 的恒河猴大脑中 NEUROKININ-1 受体的表达
- 批准号:
8173056 - 财政年份:2010
- 资助金额:
$ 23.82万 - 项目类别:
Anti-HIV Neuroimmunomodulatory Therapy with Neurokinin-1 (NK1-R) Antagonists
使用 Neurokinin-1 (NK1-R) 拮抗剂进行抗 HIV 神经免疫调节治疗
- 批准号:
8303327 - 财政年份:2009
- 资助金额:
$ 23.82万 - 项目类别:
相似海外基金
Multidisciplinary Evaluation of Accelerated Aging in HIV-1 Infection
HIV-1 感染加速衰老的多学科评估
- 批准号:
9271038 - 财政年份:2017
- 资助金额:
$ 23.82万 - 项目类别:
IL-23/STAT3-Driven Oral Immune Responses to Candida albicans
IL-23/STAT3 驱动的针对白色念珠菌的口腔免疫反应
- 批准号:
8977508 - 财政年份:2014
- 资助金额:
$ 23.82万 - 项目类别:
Identifying the ligand for the activating NK cell receptor KIR3DS1 and its protective role in HIV-1 disease progression
鉴定激活 NK 细胞受体 KIR3DS1 的配体及其在 HIV-1 疾病进展中的保护作用
- 批准号:
8846812 - 财政年份:2014
- 资助金额:
$ 23.82万 - 项目类别:
Identifying the ligand for the activating NK cell receptor KIR3DS1 and its protective role in HIV-1 disease progression
鉴定激活 NK 细胞受体 KIR3DS1 的配体及其在 HIV-1 疾病进展中的保护作用
- 批准号:
8991842 - 财政年份:2014
- 资助金额:
$ 23.82万 - 项目类别:
IL-23/STAT3-Driven Oral Immune Responses to Candida albicans
IL-23/STAT3 驱动的针对白色念珠菌的口腔免疫反应
- 批准号:
9193080 - 财政年份:2014
- 资助金额:
$ 23.82万 - 项目类别: